



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmcbac@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION I

Invitation to Bid

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City 1100

website: www.pcmc.gov.ph email: officeofthedirector@pcmc.gov.ph

Trunkline: 588-9900 DirectLine: 924-0836 Fax No: 924-0840

**INVITATION TO BID NO
IB 2021-144**

1. The **Philippine Children's Medical Center (PCMC)** through the **GAA CY 2021** intends to apply the sum of **Seven Million One Hundred Sixty-Five Thousand Six Hundred Seventy-Eight Pesos and 10/100 (Php 7,165,678.10)** being the Approved Budget for the Contract (ABC) to payments under the following Invitation to Bid. Bids received in excess of the ABC shall be automatically rejected at bid opening.

DESCRIPTION	Total Cost	Cost of Bidding Docs
Supply and Delivery of Various Pharmaceutical Supplies CY 2021	7,165,678.10	10,000.00

2. The **Philippine Children's Medical Center (PCMC)** now invites bids for the above-mentioned project. Delivery of the Goods is required **within Seven (7) calendar days from receipt of Purchase Order / Delivery Order Slip**. Bidders should have completed, within the **past two (2) years** from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II. Instructions to Bidders.

3. Bidding will be conducted through open competitive bidding procedures using a nondiscretionary "pass/fail" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the "Government Procurement Reform Act".

- a. Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.

4. Prospective Bidders may obtain further information from PCMC and inspect the Bidding Documents at the address given below during office hours.

5. A complete set of Bidding Documents may be acquired by interested Bidders **starting September 28, 2021** upon payment of the applicable fee stated above. It may also be downloaded free of charge from the website of the Philippine Government Electronic Procurement System (PhilGEPS) and the website of PCMC, provided that Bidders shall pay the applicable fee for the Bidding Documents not later than the submission of their bids.

6. The Philippine Children's Medical Center will hold a **Pre-Bid Conference on October 6, 2021 at 10:00 A.M.** through video conferencing via *google meet* (meet.google.com/xaz-wohz-xcc) which shall be open to prospective bidders.

PhilHealth Accredited



7. Bids must be duly received through manual submission on or before **October 18, 2021 1:30 P.M., Guard-on-Duty, 3rd Floor, Procurement Division Area, PCMC Main Building.** Late bids shall not be accepted.

8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in ITB Clause 14.

9. Bid opening shall be on **October 18, 2021, 2:00 P.M. 3rd Floor, Function Hall, PCMC Main Building.** Bids will be opened in the presence of the Bidders' representatives who choose to attend at the afore-mentioned venue. In compliance to social distancing and to support the government's effort to mitigate, if not contain the transmission of COVID-19, we will strictly allow only one authorized representative per bidder company to enter the venue during opening of bids. Provided further, that said authorized representative shall follow PCMC's safety protocol by wearing face mask and face shield and shall pass the triage areas as required prior entering PCMC Premises.

10. The **Philippine Children's Medical Center (PCMC)** reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.


11. For further information, please refer to:

Procurement Division
3rd Floor, Procurement Division Area
PCMC Main Building
Quezon Avenue, cor. Agham Road Quezon City
Trunkline : 8588-9900 Loc 361 / 355
Fax Number: 924-0870
Email : pcmcbac@gmail.com

12. You may visit the following websites:

For downloading of Bidding Document : www.pcmc.gov.ph
www.philgecps.gov.ph

September 27, 2021


MARIA ROSARIO S. CRUZ, MD, FPPS, FPSN, FPNSP
Chairman, Bids & Awards Committee



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: bac@pcmc.gov.ph
Trunkline: 588-9900 local 361/355 Telefax No.: 924-0870

SECTION II

Instructions to Bidders

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

1. Scope of Bid

The **Philippine Children's Medical Center (PCMC)** wishes to receive Bids for the following Project:

IB NUMBER	ITEM DESCRIPTION	TOTAL ABC
IB-2021-144	Supply and Delivery of Various Pharmaceutical Supplies CY 2021	7,165,678.10

The above Procurement Projects, the details of which are described in Section VII (Technical Specifications).

2. Funding Information

- 2.1. The GOP through the source of funding as indicated below for **CY 2021** in the amount of **Seven Million One Hundred Sixty-Five Thousand Six Hundred Seventy-Eight Pesos and 10/100 (Php 7,165,678.10)**.
- 2.2. The source of funding is:
 - a. GOCC and GFIs, the Corporate Operating Budget (*Revolving Fund*)

3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **IB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex "I" of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

5. Eligible Bidders

- 5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.

5.2.

- a. Foreign ownership exceeding those allowed under the rules may participate pursuant to:
 - i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;
 - ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;
 - iii. When the Goods sought to be procured are not available from local suppliers; or
 - iv. When there is a need to prevent situations that defeat competition or restrain trade.

5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at least one (1) contract similar to the Project the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:

- a. For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC of the items joined.
- b. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements: [*Select either failure or monopoly of bidding based on market research conducted*]
 - i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *fifty percent (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies*] of the ABC for this Project; and
 - ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.

5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under **ITB** Clause 18.

7. Subcontracts

- 7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that:

- a. Subcontracting is not allowed.

8. Pre-Bid Conference

The Philippine Children's Medical Center will hold a Pre-Bid Conference on **October 6, 2021 at 10:00 A.M.** through video conferencing via google meet which shall be open to prospective bidders, as indicated in paragraph 6 of the **IB**.

9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

10. Documents comprising the Bid: Eligibility and Technical Components

- 10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 10.2. The Bidder's SLCC as indicated in **ITB** Clause 5.3 should have been completed within **the past two (2) years** prior to the deadline for the submission and receipt of bids.
- 10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

11. Documents comprising the Bid: Financial Component

- 11.1. The second bid envelope shall contain the financial documents for the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.
- 11.3. Any bid exceeding the ABC indicated in paragraph 1 of the **IB** shall not be accepted.

- 11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.

12. Bid Prices

- 12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:
- a. For Goods offered from within the Procuring Entity's country:
 - i. The price of the Goods quoted EXW (ex-works, ex-factory, ex-warehouse, ex-showroom, or off-the-shelf, as applicable);
 - ii. The cost of all customs duties and sales and other taxes already paid or payable;
 - iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and
 - iv. The price of other (incidental) services, if any, listed in e.
 - b. For Goods offered from abroad:
 - i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.
 - ii. The price of other (incidental) services, if any, as listed in **Section VII (Technical Specifications)**.

13. Bid and Payment Currencies

- 13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.
- 13.2. Payment of the contract price shall be made in:
- a. Philippine Pesos.

14. Bid Security

- 14.1. The Bidder shall submit a Bid Securing Declaration¹ or any form of Bid Security in the amount indicated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.

14.2. The Bid and bid security shall be valid until **120 calendar days**. Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

15. Sealing and Marking of Bids

Use of indelible ink **color blue** shall be used by the authorized signatory in signing the required forms. **Strictly NO using of staple wire and thick materials for tab**

The **First (1st) Envelope**, shall contain the following Technical Documents accomplished in two (2) sets, **each set filed in a folder**

The **Second (2nd) Envelope** shall contain the Financial Component accomplished in three (3) sets, **each set filed in a folder**

All copies should be certified as true copy

COLOR CODING OF FOLDERS/ENVELOPES	PINK
--	-------------

LABEL ON THE ENVELOPE/S:

Name of PROCURING ENTITY
Name of CONTRACT TO BE BID
IB Number
DATE of Bid Opening
Name of the Bidder Company
Address of the Bidder Company

IDENTIFY THE ENVELOPES:

as: > Technical Component Requirements
(original and copy 1)
> Financial Component Requirement
(original, copy 1, copy 2)

16. Deadline for Submission of Bids

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB**.

17. Opening and Preliminary Examination of Bids

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

18. Domestic Preference

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

19. Detailed Evaluation and Comparison of Bids

19.1. The Procuring BAC shall immediately conduct a detailed evaluation of all Bids rated "*passed*," using non-discretionary pass/fail criteria. The BAC shall consider

the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.

- 19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case maybe. In this case, the Bid Security as required by **ITB** Clause 15 shall be submitted for each lot or item separately.
- 19.3. The descriptions of the lots or items shall be indicated in **Section VII (Technical Specifications)**, although the ABCs of these lots or items are indicated in the **BDS** for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.
- 19.4. The Project shall be awarded as follows:

Option 3 - One Project having several items, which shall be awarded as separate contracts per item.
- 19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

20. Post-Qualification

- 20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**.

21. Signing of the Contract

- 21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.

CONFORME:

Authorized Signatory
Signature over printed name

Name of Company/Firm



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmbac@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION III

Bid Data Sheet

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

Bid Data Sheet

ITB Clause							
5.3	<p>For this purpose, contracts similar to the Project shall be:</p> <ol style="list-style-type: none"> a. Supply and delivery of <i>Pharmaceutical Supplies</i>. b. completed within <i>the last two (2) years</i> prior to the deadline for the submission and receipt of bids. 						
7.1	Subcontracting is not allowed.						
12	The Bid prices for Goods supplied from outside of the Philippines shall be quoted in Philippine Pesos.						
14.1	<p>The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts:</p> <ol style="list-style-type: none"> 1. The amount of not less than two percent (2%) of the ABC of the item(s) joined, if bid security is in cash, cashier's/manager's check, bank draft/guarantee or irrevocable letter of credit; or 2. The amount of not less than five percent (5%) of the ABC of the item(s) joined, if bid security is in Surety Bond. 						
19.3	<p><i>Supply and Delivery of the following:</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center;">IB NUMBER</th> <th style="text-align: center;">ITEM DESCRIPTION</th> <th style="text-align: center;">TOTAL ABC</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">IB-2021-144</td> <td style="text-align: center;">Pharmaceutical Supplies CY 2021</td> <td style="text-align: right;">7,165,678.10</td> </tr> </tbody> </table>	IB NUMBER	ITEM DESCRIPTION	TOTAL ABC	IB-2021-144	Pharmaceutical Supplies CY 2021	7,165,678.10
IB NUMBER	ITEM DESCRIPTION	TOTAL ABC					
IB-2021-144	Pharmaceutical Supplies CY 2021	7,165,678.10					
20.2	<p>The Lowest Calculated Bidder shall submit the following documentary requirements within a non-extendible period of <i>five (5) calendar days</i> from receipt of the notification that contain the following:</p> <ol style="list-style-type: none"> 1. Latest Income and Business Tax Returns filed and paid through the BIR Electronic Filing (EFPS) within the last three (3) months 2. Valid and current Certificate of PhilGEPS Registration. 3. Manufacturer's Certification or if the Bidder is not a manufacturer, authenticated copy of certification from the manufacturer as authorized or exclusive distributor or dealer of the products / items. 4. Valid and current Certificate of Product Registration issued Food and Drugs Administration (FDA). 5. With manufacturer and/or products certification by an independent 3rd party Certifying body (ISO 14020, 14021, 14024, 14025 or its equivalent), is preferred. 6. Consumer guidelines regarding disposal of the supplies (<i>Information about how and where the used/decommissioned products/ packaging/parts can be returned for recycling and/or disposal e.g. buy-back program</i>) 						

	<p>7. Other appropriate licenses and permits required by law and stated in the Bidding Documents</p> <p>Failure of the Bidder declared as LCB to duly submit the requirements stated above or a finding against the veracity of such shall be ground for forfeiture of the bid security and disqualify the Bidder for award.</p> <p><i>Note: Requirement Nos. 3 to 6 for items JOINED must be accomplished and submitted using the Summary Sheet to be provided by PCMC.</i></p>
21.2	<i>No additional contract documents relevant to the Project</i>

CONFORME:

 Authorized Signatory
 Signature over printed name

 Name of Company/Firm



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmcba@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION IV

General Conditions of Contract

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

1. Scope of Contract

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract (SCC)**.

2. Advance Payment and Terms of Payment

2.1. Advance payment of the contract amount is provided under Annex "D" of the revised 2016 IRR of RA No. 9184.

2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the **SCC**.

[Include the following clauses if Framework Agreement will be used:]

2.3. For a single-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier in its bid.

2.4. For multi-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier during conduct of Mini-Competition.

3. Performance Security

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184. *[Include if Framework Agreement will be used:]* In the case of Framework Agreement, the Bidder may opt to furnish the performance security or a Performance Securing Declaration as defined under the Guidelines on the Use of Framework Agreement.

4. Inspection and Tests

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project *[Include if Framework Agreement will be used:]* or Framework Agreement specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the **SCC, Section IV (Technical Specifications)** shall specify what inspections and/or tests the Procuring Entity requires, and where they are to be conducted. The Procuring Entity

shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

5. Warranty

- 6.1. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.
- 6.2. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

6. Liability of the Supplier

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

CONFORME:

Authorized Signatory
Signature over printed name

Name of Company/Firm



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmcba@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION V

Special Conditions of Contract

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

Special Conditions of Contract

GCC Clause	
	<p><i>For Goods supplied from within the Philippines:</i></p> <p>Upon delivery of the Goods to the Project Site, the Supplier shall notify the Procuring Entity and present the following documents to the Procuring Entity:</p> <ul style="list-style-type: none"> (i) Original and four copies of the Supplier’s invoice showing Goods’ description, quantity, unit price, and total amount; (ii) Four copies of Material Safety Data Sheet for a specified product upon initial delivery
	<p>Packaging –</p> <p>The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the Goods’ final destination and the absence of heavy handling facilities at all points in transit</p> <p>The packaging, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified below, and in any subsequent instructions ordered by the Procuring Entity.</p> <p>The Supplier shall have an established disposal and retrieval program or take back system for their products (items with container)</p> <ol style="list-style-type: none"> 1 The Supplier shall submit MSDS for a specified product. 2. The product label shall bear the following information: <ol style="list-style-type: none"> a. Product specifications and ingredients b. Manufacturing and Expiration Dates c. Precautions d. Instructions for proper use and disposition e. Hazardous items shall be properly labeled as a hazardous product (e.g. flammable cytotoxic, radioactive, poison, etc.) 3. The product shall not contain halogenated plastics and PVCs. 4. The product shall be packed in suitable packaging materials which are reusable and recyclable.
	<p>Transportation –</p> <p>Where the Supplier is required under Contract to deliver the Goods CIF, CIP, or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price.</p> <p>Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the contract price.</p>

	<p>Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the Procuring Entity certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered force majeure.</p> <p>The Procuring Entity accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the Procuring Entity until their receipt and final acceptance at the final destination.</p> <p>Intellectual Property Rights –</p> <p>The Supplier shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof.</p>
2.2	<p>The terms of payment shall be on Acceptance:</p> <p>100% of the Contract Price per Delivery Order Slip shall be paid to the Supplier within 30 to 45 days or Supplier's credit term after final acceptance and submission of required documents.</p>
3	<p>Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security.</p>
4	<p>The inspections and tests that will be conducted are:</p> <p>1) Upon delivery, the Goods shall undergo preliminary physical inspection by the Inspection Team of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods.</p> <p>2) The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY.</p>
5	<p>Three (3) months after acceptance by the Procuring Entity of the delivered Goods or after the Goods are consumed, whichever is earlier.</p> <p>Winning bidder has to choose the following mode (as checked) as the form of retention money required of under R.A 9184 Sec. 62.1</p> <p style="text-align: center;"> <input type="checkbox"/> Bank Guarantee <input type="checkbox"/> 5% Deduction from claims </p> <p>The said amount shall only be released after the lapse of the warranty period specified in Section VII Technical Specification; provided, however, that the Supplies delivered are free from patent and latent defects and all the conditions imposed under this Contract have been fully met.</p>

CONFORME:

Authorized Signatory
Signature over printed name

Name of Company/Firm



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmcbaac@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VI

Schedule of Requirements

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

The delivery schedule expressed as weeks/months stipulates hereafter a delivery date which is the date of delivery to the project site.

Description	Total ABC (Php)	Delivery Site	PCMC Requirement DELIVERY PERIOD
Various Pharmaceutical Supplies CY 2021	Php7,165,678.10	Materials Management Division, G/F PCMC, Quezon Avenue, cor . Agham Road Quezon City	Within seven (7) working days from receipt of DELIVERY ORDER SLIP

DELIVERY AND ACCEPTANCE

- Staggered delivery and staggered payment
- Supplies to be delivered should have an expiration at least one (1) year and longer or as expressed/required by the end-user.
- The Supplier should submit Materials Safety Data Sheet upon initial delivery, if applicable.
- The supplier should deliver the goods called for in the Purchase Order (PO) within seven (7) working days or as stated on Delivery Period upon receipt of approved Delivery Order Slip, faxed or personally received during office hours at the Procurement Section.
- All goods delivered pursuant to the Purchase Order (PO) with Delivery Order Slip shall be subject to acceptance and inspection by the end-user as well as by the House Inspector and of the Resident Auditor or their representatives. Goods delivered not in conformity with specifications shall be rejected and the contractor held in default.

CONFORME:

NAME OF COMPANY

ADDRESS

SIGNATURE OVER PRINTED NAME
OF AUTHORIZED REPRESENTATIVE

TELEPHONE / FAX



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmcba@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VII

Technical Specifications

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

PHILIPPINE CHILDREN'S MEDICAL CENTER
Quezon Avenue, Quezon City

Name of Project : VARIOUS PHARMACEUTICAL SUPPLIES CY 2021

Total ABC = Php5,878,929.80

Invitation to Bid No. IB 2021-144-A

TECHNICAL SPECIFICATIONS

PCMC's REQUIREMENT				BIDDER'S OFFER		
Item No.	Qty	Unit	Item Description	ITEM DESCRIPTION (Specification, Packing, etc.)	BRAND	MANUFACTURER
1	1,800	bt/bag	05% D in 0.45% NaCl 1L (IV inf)			
2	3,000	vl	50% D in W (D50-50) vl 50mL (IV)			
3	7,500	amp	Acetylcysteine amp 100mg/mL 3mL (IMIV)			
4	800	amp	Acetylcysteine amp 100mg/mL, 3mL inhalation			
5	1,000	amp	Atropine Sulf amp 1mg/mL, 1mL (IM,IV)			
6	18,000	tab	Baclofen tab 10mg blister/foil pack			
7	600	neb	Budesonide Resp soln 250mcg/mL, 2mL (unit dose)			
8	7,380	tab	Calcium Carbonate tablet/chewable 500mg			
9	100	bt	Cefalexin Monohyd syr/susp bt 250mg/5mL, 60mL			
10	3,000	tab	Cetirizine Dihydrochloride tab 10mg blister/foil pack			
11	812	tab	Deferasirox 250mg dispersible tablet			
12	600	tab	Domperidone tab 10mg blister/foil pack			
13	684	vl	Factor VIII Conc lyoph powd vl + diluent (IV) 50 IU/mL			
14	1,600	cap/tab	Folic Acid 5mg blister/foil pack			
15	150	bt/bag	Hypertonic Lactate Soln 250mL (IV inf)			
16	200	pc	IV Catheter g18			
17	400	amp	Ketorolac trometamol amp 30mg/mL, 1mL (IM,IV)			
18	3,810	tab	Lamotrigin 50mg tablet			
19	700	tab	Medroxyprogesterone acetate tab 10mg			
20	200	bt	Multivitamins drp bt 15mL			
21	500	tbe	Mupirocin oint tube 2% 5g			

Name of Project : VARIOUS PHARMACEUTICAL SUPPLIES CY 2021

Total ABC = Php5,878,929.80

Invitation to Bid No. IB 2021-144-A

TECHNICAL SPECIFICATIONS

PCMC's REQUIREMENT				BIDDER'S OFFER		
Item No.	Qty	Unit	Item Description	ITEM DESCRIPTION (Specification, Packing, etc.)	BRAND	MANUFACTURER
22	500	vf	Paracetamol 10mg/mL, 100mL Soln for infusion (IV)			
23	2,000	amp	Paracetamol 150mg/mL, 2mL Soln for injection (IM/IV)			
24	60	bt	Sevoflurane inhalation bt 250mL			
25	1,130	vl	Sodium Bicarbonate vl 1mEq/mL, 20mL (IV inf)			
26	40	vl	Thiopental Sodium 500mg powder for Injection (IV)			
27	1,200	cap	Ursodeoxycholic Acid cap 250mg blister/foil pack			
28	30	vl	Vasopressin 20 IU/mL 1mL			

Additional Requirements :

- Products to be bided should have passed the end-user's evaluation

NAME OF COMPANY

ADDRESS

SIGNATURE OVER PRINTED NAME

TELEPHONE / FAX NO.

PRICE SCHEDULE

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER	NAME OF BIDDER:
NAME OF PROJECT: PHARMACEUTICAL SUPPLIES CY 2021	INVITATION TO BID NO. IB-2021-144-A

ITEM NO.	PCMC REQUIREMENT					BIDDER'S OFFER									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
	ITEM DESCRIPTION	QTY	UNIT	ABC PER UNIT	TOTAL ABC	ITEM DESCRIPTION	BRAND	MANUFACTURER	COUNTRY OF ORIGIN	UNIT PRICE EXW	COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT	TOTAL PRICE EXW (cols. 2 x 10)	UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES	SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED	TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2
1	05% D in 0.45% NaCl 1L (IV inf)	1,800	bt/ bag	210.00	378,000.00										
2	50% D in W (D50-50) v1 50mL (IV)	3,000	vl	26.00	78,000.00										
3	Acetylcysteine amp 100mg/mL 3mL (IMIV)	7,500	amp	92.40	693,000.00										
4	Acetylcysteine amp 100mg/mL, 3mL inhalation	800	amp	84.00	67,200.00										
5	Atropine Sulf amp 1mg/mL, 1mL (IM,IV)	1,000	amp	10.73	10,730.00										
6	Baclofen tab 10mg blister/foil pack	18,000	tab	15.00	270,000.00										
7	Budesonide Resp soln 250mcg/mL, 2mL (unit dose)	600	neb	34.25	20,550.00										
8	Calcium Carbonate tablet/chewable 500mg	7,380	tab	6.50	47,970.00										
9	Cefalexin Monohyd syr/susp bt 250mg/5mL, 60mL	100	bt	28.15	2,815.00										

PRICE SCHEDULE

PROCURING ENTITY: **PHILIPPINE CHILDREN'S MEDICAL CENTER**

NAME OF BIDDER:

NAME OF PROJECT: **PHARMACEUTICAL SUPPLIES CY 2021**

INVITATION TO BID NO. **IB-2021-144-A**

PCMC REQUIREMENT					BIDDER'S OFFER										
ITEM NO.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
	ITEM DESCRIPTION	QTY	UNIT	ABC PER UNIT	TOTAL ABC	ITEM DESCRIPTION	BRAND	MANUFACTURER	COUNTRY OF ORIGIN	UNIT PRICE EXW	COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT	TOTAL PRICE EXW (cols. 2 x 10)	UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES	SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED	TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2
10	Cetirizine Dihydrochloride tab 10mg blister/foil pack	3,000	tab	3.42	10,260.00										
11	Deferasirox 250mg dispersible tablet	812	tab	493.30	400,559.60										
12	Domperidone tab 10mg blister/foil pack	600	tab	1.60	960.00										
13	Factor VIII Conc lyoph powd v1 + diluent (IV) 50 IU/mL	684	vl	4,040.00	2,763,360.00										
14	Folic Acid 5mg blister/foil pack	1,600	cap/tab	2.75	4,400.00										
15	Hypertonic Lactate Soln 250mL (IV inf)	150	bt/bag	797.41	119,611.50										
16	IV Catheter g18	200	pc	30.00	6,000.00										
17	Ketorolac trometamol amp 30mg/mL, 1mL (IM,IV)	400	amp	16.00	6,400.00										
18	Lamotrigin 50mg tablet	3,810	tab	5.37	20,459.70										

PRICE SCHEDULE

PROCURING ENTITY: **PHILIPPINE CHILDREN'S MEDICAL CENTER**

NAME OF BIDDER:

NAME OF PROJECT: **PHARMACEUTICAL SUPPLIES CY 2021**

INVITATION TO BID NO. **IB-2021-144-A**

PCMC REQUIREMENT					BIDDER'S OFFER										
ITEM NO.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
	ITEM DESCRIPTION	QTY	UNIT	ABC PER UNIT	TOTAL ABC	ITEM DESCRIPTION	BRAND	MANUFACTURER	COUNTRY OF ORIGIN	UNIT PRICE EXW	COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT	TOTAL PRICE EXW (cols. 2 x 10)	UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES	SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED	TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2
19	Medroxyprogesterone acetate tab 10mg	700	tab	85.50	59,850.00										
20	Multivitamins drp bt 15mL	200	bt	28.00	5,600.00										
21	Mupirocin oint tube 2% 5g	500	tbe	66.00	33,000.00										
22	Paracetamol 10mg/mL, 100mL Soln for infusion (IV)	500	vl	128.88	64,440.00										
23	Paracetamol 150mg/mL, 2mL Soln for injection (IM/IV)	2,000	amp	27.00	54,000.00										
24	Sevoflurane inhalation bt 250mL	60	bt	8,500.00	510,000.00										
25	Sodium Bicarbonate vl 1mEq/mL, 20mL (IV inf)	1,130	vl	110.00	124,300.00										
26	Thiopental Sodium 500mg powder for Injection (IV)	40	vl	960.00	38,400.00										
27	Ursodeoxycholic Acid cap 250mg blister/foil pack	1,200	cap	36.97	44,364.00										

PRICE SCHEDULE

PROCURING ENTITY: **PHILIPPINE CHILDREN'S MEDICAL CENTER**

NAME OF BIDDER:

NAME OF PROJECT: **PHARMACEUTICAL SUPPLIES CY 2021**

INVITATION TO BID NO. **IB-2021-144-A**

PCMC REQUIREMENT						BIDDER'S OFFER									
ITEM NO.	1 ITEM DESCRIPTION	2 QTY	3 UNIT	4 ABC PER UNIT	5 TOTAL ABC	6 ITEM DESCRIPTION	7 BRAND	8 MANUFACTURER	9 COUNTRY OF ORIGIN	10 UNIT PRICE EXW	11 COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT	12 TOTAL PRICE EXW (cols. 2 x 10)	13 UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES	14 SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED	15 TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2
28	Vasopressin 20 IU/ mL 1mL	30	vl	1,490.00	44,700.00										
ADDITIONAL REQUIREMENTS:										TOTAL =					
<ul style="list-style-type: none"> ➤ Conforms on the attached Terms of Reference, if applicable ➤ Drugs and Medicines to be delivered should have expiration of at least one (1) year and longer or as expressed/ required by Pharmacy ➤ The price of the bided item(s) shall be valid until December 31, 2021 ➤ Staggered delivery, staggered payment ➤ The quantities specified are estimated requirements during the period and may be decreased depending upon the actual need of PCMC. It is understood therefore that PCMC is not bound to order / purchase all the items / quantities called for on this biddin ➤ The supplier should submit Materials Safety Data Sheet upon delivery, if applicable ➤ PCMC has the right to reject any or all bids without offering any reason, waive any required formality and award the contract to any bidder whose proposals as evaluated by PCMC is the most advantageous to the government. 										<p>TERMS OF PAYMENT (For discounts being offered, if there's any. Otherwise, state "NONE") :</p> <p style="text-align: center;"><i>NAME AND SIGNATURE OF AUTHORIZED REPRESENTATIVE</i></p> <p>BAC & END-USER'S SIGNATURE:</p>					

Name of Project : VARIOUS PHARMACEUTICAL SUPPLIES CY 2021

Total ABC = Php1,286,748.30

Invitation to Bid No. IB 2021-144-B

TECHNICAL SPECIFICATIONS

PCMC's REQUIREMENT				BIDDER'S OFFER		
Item No.	Qty	Unit	Item Description	ITEM DESCRIPTION (Specification, Packing, etc.)	BRAND	MANUFACTURER
1	70	vl	Amphotericin B 50mg lyophilized powder vl (IV)			
2	1,600	vl	Ampicillin Sod 500mg + Sulbactam 250mg vl (IM,IV)			
3	210	bag	CAPD Solution 2.5% 2L with cap			
4	300	vl	Doxorubicin HCl powd/solution vl 10mg (IV)			
5	384	pc	Epoetin A (RH Erythropoetin) pfs 4000 IU/0.4mL (IV,SC)			
6	510	pc	Epoetin B (RH Erythropoetin) pfs 2000 IU/0.3mL (IV,SC)			
8	1,500	vl	Heparin Sod (unfractionated) vl 1000IU/mL, 5mL (IV,SC)			
9	2,800	tab	Imatinib 100mg tab			
10	800	vl	Insulin Biphasic Isophane Human (recomb DNA)70/30, 10mL (IM,SC)			
11	900	tab	Methyldopa tab 250mg blister/foil pack			
13	2,200	tab	Mycophenolate Mofetil tab 500mg			
16	1,950	tab	Sevelamer Carbonate 800mg tablet			
18	1,500	tab	Spirolactone tab 25mg blister/foil pack			

Additional Requirements :

- Products to be bided should have passed the end-user's evaluation

NAME OF COMPANY

ADDRESS

SIGNATURE OVER PRINTED NAME

TELEPHONE / FAX NO.

PRICE SCHEDULE

PROCURING ENTITY: **PHILIPPINE CHILDREN'S MEDICAL CENTER**

NAME OF BIDDER:

NAME OF PROJECT: **PHARMACEUTICAL SUPPLIES CY 2021**

INVITATION TO BID NO. **IB-2021-144-B**

PCMC REQUIREMENT					BIDDER'S OFFER										
ITEM NO.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
	ITEM DESCRIPTION	QTY	UNIT	ABC PER UNIT	TOTAL ABC	ITEM DESCRIPTION	BRAND	MANUFACTURER	COUNTRY OF ORIGIN	UNIT PRICE EXW	COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT	TOTAL PRICE EXW (cols. 2 x 10)	UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES	SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED	TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2
1	Amphotericin B 50mg lyophilized powder v1 (IV)	70	vl	790.24	55,316.80										
2	Ampicillin Sod 500mg + Sulbactam 250mg v1 (IM,IV)	1,600	vl	83.60	133,760.00										
3	CAPD Solution 2.5% 2L with cap	210	bag	190.00	39,900.00										
4	Doxorubicin HCl powd/solution v1 10mg (IV)	300	vl	159.00	47,700.00										
5	Epoetin A (RH Erythropoietin) pfs 4000 IU/0.4mL (IV,SC)	384	pc	380.00	145,920.00										
6	Epoetin B (RH Erythropoietin) pfs 2000 IU/0.3mL (IV,SC)	510	pc	460.00	234,600.00										
8	Heparin Sod (unfractionated) v1 1000IU/mL, 5mL (IV,SC)	1,500	vl	75.00	112,500.00										
9	Imatinib 100mg tab	2,800	tab	85.00	238,000.00										
10	Insulin Biphasic Isophane Human (recomb DNA)70/30, 10mL (IM,SC)	800	vl	78.00	62,400.00										
11	Methyldopa tab 250mg blister/ foil pack	900	tab	9.00	8,100.00										

PHILIPPINE CHILDREN'S MEDICAL CENTER
Quezon Avenue, Quezon City

TERMS OF REFERENCE
CY 2021

Pharmaceutical Products, Containers, and Devices

The following are the requirements to winning suppliers in compliance with Administrative Order No. 2019-0041, dated October 4, 2019 re: *Implementing Guidelines in Assuring the Efficacy, Quality, and Safety of Pharmaceutical Products in the Public Health Facilities*;

1. All pharmaceutical products and devices shall be of fresh commercial stock as reflected in the Certificate of Product Registration (CPR) issued by the FDA upon delivery. The acceptable shelf life upon delivery is as follows:

Claimed Shelf Life in CPR	Minimum Remaining Shelf Life Upon Delivery
60 months	42 – 60 months
48 months	34 – 48 months
36 months	30 – 36 months
24 months	18 – 24 months
18 months	12 – 18 months
12 months	12 months

2. The CPR must be valid for the entire period of the award. If the CPR is about to expire, the supplier must have submitted a copy of an application of renewal to the FDA at least 3 months before the expiry date (a copy of the expiring CPR which is stamped with an “extension of validity” shall be submitted as proof).
3. The Pharmacist-in-charge of inspection and acceptance of pharmaceutical products and devices shall conduct random sampling of the products delivered for batch testing.
 - 3.1 The samples collected shall be submitted to FDA for test analysis. The Pharmacist shall determine the kind of test(s) to be done based on the physical inspection done. (Annex A)
 - 3.2 The supplier shall replace (same batch) or pay the cost of the samples collected for testing.
 - 3.3 The supplier shall pay the cost of testing of the products collected.
4. The supplier shall be provided with a copy of the result of tests analysis done on their products.
5. The supplier shall submit the batch notification for antibiotic products and batch certificate for vaccines issued by the FDA upon delivery.

6. The performance of the suppliers shall be monitored based on the following Key Performance Indicators:

6.1 Suppliers meet quality and service standards specified in the Terms of Reference (TOR)/Purchase Order (PO)/Contract

6.2 Timeliness of delivery

6.3 Completeness of quantity delivered

6.4 Zero defects of products

6.5 Relevant additional services provided (e.g. disposal, recall)

CONFORME :

Authorized Signatory
Signature over printed name

Name of Company / Firm

ANNEX A

Minimum Number of Sample Units Required for Each Test Analysis (FDA Circular No. 2014-014 dated 16 March 2014)

PHARMACEUTICAL PRODUCTS

a. Microbiological Tests

Sample Type	Test Parameter	Number of Sample Units
Nonaqueous/aqueous preparation for oral use	<ul style="list-style-type: none"> • Total Aerobic Microbial Count • Total Combined Yeast & Mold Count • Absence of Escherichia coli in 1g or mL 	Minimum of 2 commercial presentations with a total net weight or volume of not less than 50g or mL
Rectal Use	<ul style="list-style-type: none"> • Total Aerobic Microbial count • Total Combined Yeast & Mold Count 	
Oromucosal/Gingival/Cutaneous/Nasal/Auricular use	<ul style="list-style-type: none"> • Total Aerobic Microbial Count • Total Combined Yeast & Mold Count • Absence of Staphylococcus aureus in 1g or mL • Absence of Pseudomonas Aeruginosa in 1 g or mL 	
Inhalation use (special requirements apply to liquid preparations for nebulization)	<ul style="list-style-type: none"> • Total Aerobic Microbial Count • Total Combined Yeast & Mold Count • Absence of Staphylococcus aureus in 1g or mL • Absence of bile-tolerant Gram-negative bacteria in 1 g or mL 	

b. Biological Tests

Sample Type	Test Parameter	Number of Sample Units
Liquid Preparations 1mL to 100mL More than 100mL	<ul style="list-style-type: none"> • Bacterial endotoxin test 	20 bottles 6 bottles
1mL to 100mL 500 to 1000mL	<ul style="list-style-type: none"> • Sterility Test 	20 bottles 6 bottles
Solid Preparations	<ul style="list-style-type: none"> • Sterility Test 	20 units

c. Physico-chemical Tests

Sample Type	Test Parameter	Number of Sample Units
Tablet/Capsule	<ul style="list-style-type: none"> • Assay/Potency • Dissolution • Uniformity of Dosage Units • Identification Test • Disintegration • Tablet hardness 	60 tablets/capsules 50 tablets/capsules 40 tablets/capsules 20 tablets/capsules 20 tablets/capsules 10 tablets/capsules
Granules/Powder for Suspension/Syrup	<ul style="list-style-type: none"> • Assay and Minimum Fill • pH • Identification Test 	10 bottles 2 bottles 3 bottles
Injectables (1mL to 2mL)	<ul style="list-style-type: none"> • Assay/Potency • pH 	20 vials/ampules 10 vials/ampules
Injectables		20 vials/ampules

(5mL to 10mL)		5 vials/ampules
Injectables (20mL to 100mL)		10 vials/ampules 2 vials/ampules
Ointment/Cream/Gel	• Assay/Potency	10 tubes
Aerosol		10 pressurized cans
Suppositories		30 pieces

PHARMACEUTICAL CONTAINERS

Sample Type	Test Parameter	Number of Sample Units
Plastic container for suspension/syrup, oral preparations a. 10 mL b. 30 to 60 mL c. 60 to 100mL d. 250 mL e. 500 to 1000mL	• Nonvolatile residue • Residue on Ignition • Lead • Buffering Capacity	120 pcs 60 pcs 40 pcs 20 pcs 10 pcs
Plastic bottles/IV infusion a. 100mL b. 250mL c. 500 to 1000mL	• Sterility Test	15 pcs 10 pcs 6 pcs
Polyampules a. 1 to 2 mL b. 3 to 5 mL c. 6 to 10 mL		300 pcs 250 pcs 200 pcs
Vials a. 10 mL b. 20 to 25 mL c. 30 to 50 mL		120 pcs 60 pcs 30 pcs
Caps (Diameter) a. ≤ 0.5 cm b. Between 1 & 2.5 cm c. > 2.5 cm		800 pcs 48 pcs 30 pcs

DEVICES

Sample Type	Test Parameter	Number of Sample Units
Medical Devices	• Bacterial endotoxin test • Sterility Test	20 units 20 units

CONFORME :

Authorized Signatory
Signature over printed name

Name of Company / Firm

PHILIPPINE CHILDREN'S MEDICAL CENTER
Quezon Avenue, Quezon City

TERMS OF REFERENCE

CY 2021

HAZARDOUS PHARMACEUTICALS

1. The winning bidders for hazardous pharmaceuticals (see attached list) shall provide PCMC two copies (one for Property and Supply and one for the Pharmacy Division) of the corresponding Materials Safety Data Sheet (MSDS) of said medicine/galenicals upon delivery.
2. The supplier shall make sure that these pharmaceuticals are properly packed for safety from breakage and spills upon delivery to PCMC. Likewise, these pharmaceuticals shall be properly labeled as a hazardous product (e.g., flammable, cytotoxic, radioactive, poison.etc.).
3. Suppliers shall provide the PCMC with the appropriate Spill Kit upon the request of the Pharmacy Division for use in the wards/clinical areas using these products.
4. The supplier shall be responsible in disposing the expired and defective hazardous pharmaceuticals. The Pharmacy Division shall inform the corresponding supplier three months before the expiry date of their product. The supplier shall be informed about the defective products as soon as it has been detected.
5. Upon request of the corresponding end-user, the supplier shall provide training on safe handling of their product(s), including management of spills.

CONFORME :

Authorized Signatory
Signature over printed name

Name of Company / Firm

LIST OF HAZARDOUS PHARMACEUTICALS

1. Bleomycin Sulfate 15 mg inj.
2. Calcium Folate 50 mg inj.
3. Carboplatin 150 mg vl.
4. Cisplatin 50 mg vl
5. Cyclophosphamide 200 mg, 500 mg vl; 50 mg tablet
6. Cytarabine 100 mg, 500 mg, and 1 g vl.
7. Dactinomycin 500 mcg inj
8. Dacarbazine 200 mg vl.
9. Doxorubicin 10 mg, 20 mg, and 50 mg vl
10. Etoposide 20 mg/ml, 5 mL inj
11. Fluorouracil vl 500mg IV
12. Hydroxyurea 500 mg capsule
13. Idarubicin HCl 5 mg inj.
14. Ifosfamide 1 g and 2 g vl
15. Imatinib 100 mg tablet
16. Irinotecan 100 mg/5mL and 40 mg/2mL (HCl) concentrate, vl (IV infusion)
17. L-asparaginase 10,000 IU vl
18. Mercaptopurine 50 mg tab
19. Methotrexate 500 mg, 1 g, and 50 mg vl; 2.5 mg tablet
20. Mitoxanthrone 20 mg Inj.
21. Paclitaxel 6mg/mL 17mL (IV) vl
22. Rituximab 500mg inj. 50mL vial and 100mg inj. 10mL vial
23. Vinblastine 10 mg Inj
24. Vincristine 1 mg and 2 mg inj.
25. Povidone Iodine solution (all dosage preparations)
26. Gadoteric acid (all dosage preparations)
27. Iodixanol (all dosage preparations)
28. Iohexol (all dosage preparations)
29. Ioversol (all dosage preparations)
30. Iopamidol (all dosage preparations)
31. Sevoflurane Inhalation 250 mL
32. Isoflurane Inhalation 100 mL

CONFORME :

Authorized Signatory
Signature over printed name

Name of Company / Firm



Republic of the Philippines
DEPARTMENT OF HEALTH
PHILIPPINE CHILDREN'S MEDICAL CENTER
Bids and Awards Committee
Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: pcmbac@gmail.com
Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VIII

Checklist of Technical and Financial Documents

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-144

Checklist of Technical and Financial Documents

The Bidder shall submit the following **TECHNICAL COMPONENT ENVELOPE (ARRANGED, NUMBERED AND TABBED)** *[Strictly NO using of staple wire and thick materials for tabs]* as enumerated below:

I. TECHNICAL COMPONENT ENVELOPE

Class "A" Documents

Legal Documents

1. Valid PhilGEPS Registration Certification (Platinum Membership) and its Annex A.
or
2. Registration certificate from Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or Cooperative Development Authority (CDA) for cooperatives or its equivalent document,
and
3. Mayor's/Business permit issued by the city or municipality where the principal place of business of the prospective bidder is located or the equivalent document for Exclusive Economic Zones or Areas.
and
4. Valid Tax Clearance per Executive Order 398, series of 2005, as finally reviewed and approved by the BIR.

Note:

In the event the bidder opted to submit only Requirement Nos. 2 to 4 Legal Documents, the Certificate of PhilGEPS Registration (Platinum Membership) shall remain a post-qualification requirement to be submitted in accordance with Section 34.2 of the 2016 Revised IRR of RA 9184 (Pursuant to GPPB Circular 07-2017 dated 31 July 2017)

Technical Documents

5. Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid. (Use of Form No. DOBA-PCMC-SCF3b is required)
6. Statement of the bidder's Single Largest Completed Contract (SLCC) similar to the contract to be bid (**Refer to Bid Data Sheet ITB Clause 5.3**), except under conditions provided for in Sections 23.4.1.3 and 23.4.2.4 of the 2016 revised IRR of RA No. 9184, within two (2) years prior to bid opening (use of Form No. DOBA-PCMC-SCF3a is required).
7. Bid Security (**Refer to Bid Data Sheet ITB Clause 14.1**)
8. Duly accomplished and signed Production/ Delivery Schedule using the form as provided for in Section VI

The Bidder shall submit the following **FINANCIAL COMPONENT ENVELOPE (ARRANGED, NUMBERED AND TABBED)** *[Strictly NO using of staple wire and thick materials for tabs]* as enumerated below:

II. FINANCIAL COMPONENT ENVELOPE

1. Duly accomplished and signed Bid Form
2. Duly accomplished and signed **Price Schedule** using the form as provided

Note: Bidder shall return to PCMC the issued USB Flash Drive containing the soft copy of their accomplished Price Schedule (in excel format).

3. Signed Conformance on the Terms of Reference, if applicable
4. Section II. Instructions to Bidders with signature (conforme) on all pages.
5. Section III. Bid Data Sheet with signature (conforme) on all pages.
6. Section IV. General Conditions of the Contract with signature (conforme) on all pages.
7. Section V. Special Conditions of the Contract with signature (conforme) on all pages.
8. Certification for Assurance of Stocks Availability *[use of Form No. DOBA-PCMC-CAF10 is required]*
9. Return Policy *[use of Form No. DOBA – PCMC – CRF34 is required]*

CONFORME:

Authorized Signatory
Signature over printed name

Name of Company/Firm

9. Duly accomplished and signed Technical Specification using the form as provided for in Section VII
10. Omnibus Sworn Statement (Use of the Form provided is required)
11. Certificate of Performance in letterhead of their clients indicating the contact numbers and email addresses signed by the authorized head of the Department from three (3) clients of the bidder issued within the last six (6) months prior to bid opening.

Note: Certification issued by PCMC – Procurement Section must be included if bidder had done business with us. Certification of which should be of same category (e.g. equipment/supplies) of project being bided.

12. Valid and current License to Operate (LTO) issued by Food and Drug Administration (FDA).

Financial Documents

1. The prospective bidder's Audited Financial Statements, showing, among others, the prospective bidder's total current assets and liabilities, stamped "received" by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of submission.
2. The prospective bidder's computation of the Net Financial Contracting Capacity (NFCC) that must be at least equal to the ABC to be bid (*Use of Form No. DOBA-PCMC-NFF4 is required*);

OR,

a committed Line of Credit from a Universal or Commercial Bank, in lieu of its NFCC computation, it must be at least equal to 10% of the ABC.

Class "B" Documents

1. For Goods, valid joint venture agreement (JVA), in case the joint venture is already in existence. In the absence of a JVA, duly notarized statements from all the potential joint venture partners should be included in the bid, stating that they will enter into and abide by the provisions of the JVA in the event that the bid is successful. Failure to enter into a joint venture in the event of a contract award shall be ground for the forfeiture of the bid security. (*Use of Form No. DOBA-PCMC-JVF6 is required*).

Each partner of the joint venture shall submit their legal eligibility documents or Certificate of PhilGEPS Registration (Platinum Membership). The submission of technical and financial eligibility documents by any of the joint venture partners shall constitute compliance: Provided, That the partner responsible to submit the NFCC shall likewise submit the Statement of all its ongoing contracts and Audited Financial Statements.